share_log

STAAR Surgical (NASDAQ:STAA) Shares Sold by Metropolitan Life Insurance Co NY

STAAR Surgical (NASDAQ:STAA) Shares Sold by Metropolitan Life Insurance Co NY

紐約大都會人壽保險公司出售的星空外科(納斯達克代碼:STAA)股票
Defense World ·  2022/09/08 05:41

Metropolitan Life Insurance Co NY decreased its holdings in shares of STAAR Surgical (NASDAQ:STAA – Get Rating) by 85.1% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 2,994 shares of the medical instruments supplier's stock after selling 17,033 shares during the period. Metropolitan Life Insurance Co NY's holdings in STAAR Surgical were worth $239,000 at the end of the most recent quarter.

根據紐約大都會人壽保險公司向美國證券交易委員會披露的最新信息,該公司在第一季度減持了星空外科(STAAR Surgical)股票(納斯達克代碼:STAA-GET評級)85.1%。該基金在此期間出售了17,033股後,持有這家醫療器械供應商的2,994股股票。截至最近一個季度末,紐約大都會人壽保險公司持有的STAAR Surgical股份價值23.9萬美元。

Several other hedge funds have also recently modified their holdings of STAA. Rise Advisors LLC purchased a new position in shares of STAAR Surgical in the fourth quarter worth $25,000. Covestor Ltd acquired a new position in shares of STAAR Surgical in the fourth quarter valued at about $39,000. Point72 Hong Kong Ltd acquired a new stake in shares of STAAR Surgical during the fourth quarter worth about $100,000. PNC Financial Services Group Inc. increased its holdings in STAAR Surgical by 18.6% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,287 shares of the medical instruments supplier's stock worth $102,000 after buying an additional 202 shares during the period. Finally, Meeder Asset Management Inc. lifted its stake in STAAR Surgical by 815.0% during the 1st quarter. Meeder Asset Management Inc. now owns 1,345 shares of the medical instruments supplier's stock valued at $107,000 after acquiring an additional 1,198 shares during the period. Institutional investors and hedge funds own 96.38% of the company's stock.

其他幾家對衝基金最近也調整了對STAA的持股。Rise Advisors LLC在第四季度購買了STAAR Surgical的新頭寸,價值25,000美元。Covestor Ltd在第四季度收購了STAAR Surgical股票的新頭寸,價值約3.9萬美元。Point72 Hong Kong Ltd在第四季度收購了STAAR Surgical價值約10萬美元的新股。PNC金融服務集團在第一季度增持了STAAR Surgical 18.6%的股份。PNC金融服務集團現在持有這家醫療器械供應商的1,287股股票,價值102,000美元,在此期間又購買了202股。最後,彌德資產管理公司在第一季度增持了星空外科815.0%的股份。Meeder Asset Management Inc.在此期間增持了1,198股Meeder Asset Management Inc.,目前持有這家醫療器械供應商1,345股股票,價值10.7萬美元。機構投資者和對衝基金持有該公司96.38%的股票。

Get
到達
STAAR Surgical
STAAR外科
alerts:
警報:

STAAR Surgical Price Performance

STAAR手術性價比

STAA stock opened at $94.33 on Thursday. STAAR Surgical has a 1 year low of $49.03 and a 1 year high of $162.69. The firm has a market capitalization of $4.53 billion, a PE ratio of 140.79 and a beta of 1.04. The business has a 50 day simple moving average of $86.12 and a 200-day simple moving average of $73.75.

週四,Staa的股票開盤報94.33美元。STAAR Surgical的一年低點為49.03美元,一年高位為162.69美元。該公司市值為45.3億美元,市盈率為140.79,貝塔係數為1.04.該業務的50日簡單移動均線切入位在86.12美元,200日簡單移動均線切入位在73.75美元。

STAAR Surgical (NASDAQ:STAA – Get Rating) last issued its earnings results on Wednesday, August 10th. The medical instruments supplier reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.24 by $0.02. STAAR Surgical had a return on equity of 13.99% and a net margin of 12.84%. The business had revenue of $81.10 million during the quarter, compared to the consensus estimate of $80.12 million. During the same period last year, the company earned $0.19 EPS. The company's revenue for the quarter was up 30.0% on a year-over-year basis. On average, equities research analysts expect that STAAR Surgical will post 0.68 EPS for the current year.
星空外科(納斯達克代碼:STAA-GET Rating)最近一次發佈財報是在8月10日星期三。這家醫療器械供應商公佈本季度每股收益(EPS)為0.26美元,超出分析師普遍預期的0.24美元,超出0.02美元。STAAR Surgical的股本回報率為13.99%,淨利潤率為12.84%。該業務本季度的收入為8110萬美元,而普遍預期為8012萬美元。去年同期,該公司每股收益為0.19美元。該公司當季營收較上年同期增長30.0%。股票研究分析師平均預計,STAAR Surgical本年度每股收益將為0.68美元。

Wall Street Analyst Weigh In

華爾街分析師也加入進來

A number of equities analysts have weighed in on STAA shares. BTIG Research lifted their price objective on STAAR Surgical from $98.00 to $103.00 in a research note on Thursday, August 11th. Benchmark upped their price objective on shares of STAAR Surgical from $97.00 to $117.00 and gave the stock a "buy" rating in a research report on Thursday, August 11th. Canaccord Genuity Group increased their price target on STAAR Surgical from $89.00 to $97.00 in a research report on Thursday, August 11th. Jefferies Financial Group dropped their price target on shares of STAAR Surgical from $165.00 to $125.00 in a research note on Thursday, August 11th. Finally, Needham & Company LLC upped their price target on shares of STAAR Surgical from $87.00 to $110.00 and gave the stock a "buy" rating in a research report on Thursday, August 11th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, STAAR Surgical presently has an average rating of "Moderate Buy" and an average target price of $106.83.

許多股票分析師已對STAA的股票進行了加碼。BTIG Research在8月11日星期四的一份研究報告中將STAAR Surgical的目標價從98美元上調至103.00美元。在8月11日週四的一份研究報告中,Benchmark將STAAR Surgical的股票目標價從97美元上調至117.00美元,並給予該股“買入”評級。在8月11日星期四的一份研究報告中,Canaccel Genuity Group將STAAR Surgical的目標價從89.00美元上調至97.00美元。傑富瑞金融集團在8月11日星期四的一份研究報告中將STAAR Surgical的股票目標價從165.00美元下調至125.00美元。最後,Needham&Company LLC在8月11日(星期四)的一份研究報告中將STAAR Surgical的股票目標價從87美元上調至110.00美元,並給予該股“買入”評級。一位研究分析師對該股的評級為持有,五位分析師對該公司的評級為買入。根據MarketBeat.com的數據,星空外科目前的平均評級為“中等買入”,平均目標價為106.83美元。

Insider Transactions at STAAR Surgical

STAAR Surgical的內幕交易

In other STAAR Surgical news, CTO Keith Holliday sold 16,582 shares of the firm's stock in a transaction on Monday, August 15th. The stock was sold at an average price of $106.29, for a total transaction of $1,762,500.78. Following the completion of the sale, the chief technology officer now owns 19,437 shares of the company's stock, valued at $2,065,958.73. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 2.60% of the company's stock.

在STAAR Surgical的其他新聞中,CTO Keith Holliday在8月15日星期一的一次交易中出售了16,582股該公司的股票。該股以106.29美元的平均價格出售,總成交金額為176250.78美元。出售完成後,這位首席技術官現在擁有該公司19,437股股票,價值2,065,958.73美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,可以通過這個超級鏈接獲得。內部人士持有該公司2.60%的股份。

STAAR Surgical Company Profile

STAAR外科公司簡介

(Get Rating)

(獲取評級)

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.

STAAR Surgical Company與其子公司一起設計、開發、製造、營銷和銷售眼科植入性鏡片,以及將鏡片輸送到眼睛內的配套輸送系統。該公司提供治療近視、遠視、散光和老花眼等視覺障礙的Visian植入式Collamer透鏡產品系列(ICL),以及治療遠視的遠視ICL。

Featured Articles

專題文章

  • Get a free copy of the StockNews.com research report on STAAR Surgical (STAA)
  • 3 High Margin Chipmakers Bound to Recover
  • 3 Solar Stocks That Will Benefit From the Biden Tariff Holiday
  • REV Group Has A Deep Moat In The World Of EVs
  • Is G-III Apparel Group, Ltd. A Value Trap?
  • Bank Of America Sees Upside In These 2 European Alcohol Stocks
  • 免費獲取StockNews.com關於STAAR Surgical(STAA)的研究報告
  • 3家高利潤率芯片製造商勢必復甦
  • 將受益於拜登關税假期的3只太陽能股
  • REV集團在電動汽車世界擁有深厚的護城河
  • G-III服裝集團有限公司是價值陷阱嗎?
  • 美國銀行看好這兩隻歐洲酒類股票

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.

接受《STAAR外科日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對STAAR外科及相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論